Scientists discover rare genetic condition that attacks kids’ immune systems
hunter syndrome enzyme deficiency :: Article Creator Shire's Hunter Syndrome Cognitive Impairment Drug Fails Shire's attempts to develop a drug for cognitive impairment from the rare inherited disease Hunter Syndrome has failed to produce results. The company's Elaprase (idursulfase) is already approved for Hunter syndrome, and the experimental drug SHP609 was an attempt to produce a drug to treat cognitive impairment associated with the disease. Elaprase, an enzyme replacement therapy, cannot cross the blood-brain barrier, so the new formulation is injected through the spinal column. SHP609 was supposed to correct the deficiency in the iduronate-2-sulfatase enzyme in the CNS and prevent the cognitive decline seen in some Hunter Syndrome cases. Sadly, Shire said the phase 2/3 study did not meet either its primary or secondary endpoints. The primary endpoint evaluated the difference in cognition between the SHP609-treated and co...